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Background: Platelet Rich Plasma (PRP) has shown positive and long-lasting effects in
patients with tendinopathies. However, information about age-related differences in the
clinical outcome is limited. Aim of this retrospective study was to compare the efficacy
of PRP therapy in young and elderly subjects suffering for Achilles tendinopathy.
Materials and method: Patients with recalcitrant non-insertional Achilles tendinopathy
were enrolled. Clinical (VISA-A) and instrumental (ultrasonography) data were collected
at baseline and after 1, 3, 6, and 12 months. PRP injections (once a week for 3 weeks)
were performed in sterile conditions and under ultrasound (US) control.
Results: Forty-four subjects (29 young: mean age 39.5 ± 6.9; 15 elderly: mean age
61.5 ± 5.3) were retrospectively evaluated. At baseline, no significant differences were
observed in the clinical and US parameters. Throughout the whole length of the study,
a significant increase of VISA-A score was seen in both groups (from 50.3 ± 8.8 to
76.1 ± 6.6 in the young group, and from 48.7 ± 7.6 to 61.1 ± 9.4 in the elderly
group); however, the infra-groups comparison showed better results in young patients,
compared to the aged counterpart.
Conclusion: Our results show that PRP is less effective in aged people. This finding
can be ascribed to several biochemical and biomechanical differences documented in
tendons of young and elderly subjects (reduced number and functionality of tenocytes
and tenoblasts), which becomes more evident in the long-term tissue healing. However,
prospective trials, using different PRP preparations and enrolling a larger number of
subjects, are needed to draw more sound and definitive conclusions.
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INTRODUCTION
In the last decade Platelet Rich Plasma (PRP) has been extensively
used in the treatment of tendinopathies. Many trials have been
performed on diﬀerent tendons, and several PRP preparations
and treatment schedules have been proposed. These studies,
broadly speaking, have shown positive and long-lasting eﬀects
on symptoms and function in a large percentage of cases (Andia
and Abate, 2012; Andia and Maﬀulli, 2013; Andia et al., 2014).
A superiority of PRP in comparison to placebo or other usual
treatments (e.g., eccentric training, physical therapies, steroid
injections) has been observed by some authors, but not by others
(Andia and Abate, 2012; Andia and Maﬀulli, 2013; Kearney et al.,
2013; Andia et al., 2014).
Despite the large amount of data gathered in these
experiments, information about possible diﬀerence in eﬃcacy
age-related is limited. In particular, at our knowledge, only in few
papers this topic has been addressed with inconclusive results,
evaluating diﬀerent factors (age, sex, BMI, duration of symptoms,
severity of degeneration, and others), which can theoretically
inﬂuence the clinical outcomes (Ferrero et al., 2012; Boesen et al.,
2014; Filardo et al., 2014).
This is an important point, because the prevalence of
tendinopathies nowadays is increasing in aged subjects, who
practice frequently sport activities, both for leisure and for
counteracting with exercise metabolic diseases (i.e., diabetes
and obesity) (Dallaudière et al., 2013). In this framework, it
must be considered that aging itself may aﬀect biochemical and
biomechanical properties of tendons, so favoring the onset of
tendon damage.
Non-insertional Achilles tendinopathy is a very common
disease, mainly in sport-active population. Aim of this
retrospective study was to compare the eﬃcacy of PRP therapy in
young and elderly subjects, addressed to our unit for recalcitrant
non-insertional Achilles tendinopathy.
MATERIALS AND METHODS
Patients suﬀering from recalcitrant non-insertional Achilles
tendinopathy treated beforehand in our Unit with PRP were
retrospectively evaluated. Subjects who failed to respond to
conservative treatments [e.g., eccentric training, laser, Extra-
corporeal Shock Wawe, ultrasound (US), and steroid], with
history of exercise-associated pain, pain or tenderness on
palpation more than 3 months, and US features of chronic
non-insertional damage in the Achilles’ tendon were included.
Exclusion criteria were: insertional Achilles tendinopathy,
symptom duration <3 months, platelet values <150.000/mm3,
Hemoglobin values < 11 g/dl, bleeding disorders, current use of
anticoagulants or antiaggregants, hematological and rheumatic
pathologies, severe systemic diseases (renal, hepatic, cardiac,
infections, endocrinopathies, malignancies), immunodepression,
and pregnancy (Table 1).
At baseline, in all subjects, demographic (age and sex)
and anthropometric measures (height, weight, and BMI) were
registered. Clinical (symptoms duration, weekly non-steroidal
TABLE 1 | Inclusion and exclusion criteria.
Inclusion criteria Exclusion criteria
Non-insertional Achilles tendinopathy Insertional Achilles tendinopathy
Symptom duration >3 months Symptom duration <3 months
No response to conservative treatments Platelet values < 150.000/mm3
Haemoglobin values < 11 g/dl
Bleeding disorders
Ultrasound features of tendon damage Use of anticoagulants/antiaggregants
Rheumatic pathologies
Severe systemic diseases
Immunodepression
Pregnancy
anti-inﬂammatory drugs consumption, associated diseases, sport
practice) and functional data [Victorian Institute of Sports
Assessment- Achilles questionnaire (VISA-A), adapted to the
Italian language] were also collected. The VISA-A provides a
subjective functional evaluation of Achilles tendon, and consists
in eight questions which measure the domains of pain and
function in daily living and sporting activity (Abate et al., 2013).
Results range from 0 to 100, where 100 represent the perfect
score.
Ultrasound evaluation was performed by the same well-
trained operator (AM) using a high-resolution, multi-frequency
(6–15 MHz) linear array transducer (ProSound Alpha 10, Aloka,
Japan). Longitudinal and transverse scans were performed
according to standard protocols (Maﬀulli et al., 2008) with the
patient lying prone, with the feet hanging over the edge of the
table at 90◦ of ﬂexion. Loss of the normal ﬁbrillar pattern, and/or
irregularity of the tendon margins, and focal hypo-hyperechoic
areas in the musculo-tendinous junction and/or in the mid-
portion were considered as degenerative abnormalities. On the
basis of these features tendons were stratiﬁed for severity as
“mild” (one area of disorganized echotexture), “moderate” (some
areas of disorganized echotexture), and “severe” (disorganized
echotexture and diﬀuse hypo- or hyperechoic areas and/or
calciﬁcations). The presence of neovascularization, estimated
by means of Color Doppler, was graded as (0), (1+), (2+),
(3+), (4+), according to the appearance of vessels inside the
tendon (Abate et al., 2013). To avoid artifacts, sensitivity was
optimized for low ﬂow, and color gain was set just below the noise
level.
Platelet Rich Plasma was prepared using the Regen Lab
A-PRP Kit. In detail, 8 ml of autologous blood was harvested
from the cubital vein and collected into a tube containing
a citrate anti-coagulant in addition to the thixotropic cell-
separation gel. Then, the tube was carefully turn upside down
several times (×5) to homogenize the blood with the anti-
coagulant. After centrifugation [single spin, Force (RCF): 1500 g,
3400 rpm for 5 min], the blood was fractionated, with the red
blood cells trapped under the gel, and the cellular sediment,
including the platelets, settled on the surface of the gel. Therefore,
by gently inverting the tube several time, the sediment was
resuspended in the plasma supernatant, and PRP (4–5 ml,
1,6x native platelet concentration, >80% platelet recovery, no
leukocytes, red blood cell remnant <0.3%) was obtained. PRP
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TABLE 2 | Patients characteristics at baseline.
Young Elderly p
Number 29 15 –
Tendons treated 36∗ 18∗∗ –
Male:Female 19:10 13:2 –
Mean age 39.5 ± 6.9 61.5 ± 5.3 0.000
BMI 24.3 ± 1.8 25.9 ± 1.9 0.07
Symptoms duration (weeks) 28 ± 8.4 32.4 ± 6.5 0.1
Sport activities 20/29 (68.9%) 7/15 (46.6%) 0.14
Diabetes – 3/15 (%)
∧
0.01
NSAIDs consumption 5/29 (17.2%) 3/15 (20%) 0.8
VISA-A 50.3 ± 8.8 48.7 ± 7.6 0.5
∗7 and ∗∗3 bilateral.
∧
Well-controlled (self-report).
was then collected into a 10 ml luer-lock syringe and ready for
use.
After sterile dressing and under US control, small autologous
PRP depots were left at several sites into the degenerate
tendon areas, using a 21 Gage needle. PRP was placed at the
site of most damaged areas, for a total amount of 4–5 ml.
No regional anesthetic was used. A total of three injections
(once a week) was performed. After the second injection,
a rehabilitation program, based on eccentric training and
stretching, was recommended daily (3 sets × 15 repetitions)
at least for 3 months, during which a gradual return to
sport activities was encouraged. After each injection, the
patients were kept under observation for approximately 30 min
(monitoring early side eﬀects) and then discharged from the
Unit. At home, patients were asked to restrict the use of
the leg for at least 24 h; rest, ice packs, and acetaminophen
(non-steroidal anti-inﬂammatory drugs were forbidden) were
allowed. Moreover, patients were asked to register possible
adverse events (pain, swelling, heat, functional limitations) and
acetaminophen consumption during the following days after the
injection.
Functional and instrumental evaluations were repeated after
1, 3, 6, and 12 months, and patients satisfaction was registered
by means of ﬁve-points Likert Scale (Not at all satisﬁed; Slightly
satisﬁed; Somewhat satisﬁed; Very satisﬁed; Extremely satisﬁed).
Statistical Analysis
According to age, patients were divided in two diﬀerent cohorts
(Young: <55 years old; Elderly: >55 years old. This partition
was arbitrary done because a division universally accepted is not
present). Demographic, US and clinical data, before and after
treatment, were therefore compared.
Data are reported as mean ± standard deviation for
continuous variables, whereas categorical and dichotomous
variables are reported as frequencies and percentage. The
signiﬁcance level was determined at p < 0.05. The two-sample
Student’s t-test was used to compare continuous variables, when
the distribution of data was normal; the Wilcoxon’s rank sum test
was used otherwise. The χ2 test was used to evaluate associations
between categorical data. All analyses were done using SAS
statistical software, release 8.1.
RESULTS
Forty-four subjects met inclusion criteria. Demographic and
clinical data of enrolled patients are reported in Table 2, which
shows that, apart of age, and the presence of three cases of
diabetes (well-controlled, self-report) in the elderly group, no
diﬀerences were observed for other collected parameters. Neither
at the instrumental examination, signiﬁcant diﬀerence in the US
degeneration and in the neovascularization score was present
(Table 3).
No complications related to the injections or severe adverse
events were observed during the treatment and follow-up period.
Four young patients (2 at 3 months and 6 months, respectively)
and three elderly subjects (2 at 3 and 1 at 6 months, respectively)
were lost at follow-up.
The variations of VISA-A score at diﬀerent follow-up times in
the remaining patients of both groups are shown in Table 4; an
increase of VISA-A score is observed both in young and elderly
subjects throughout the whole length of the study, although with
diﬀerent levels of signiﬁcance (higher in the young).
The infra-groups comparison shows that values increase more
steadily and consistently in young patients, compared to the
aged counterpart (Figure 1). At 12 months, 18/25 (72%) young
and 6/12 (50%) elderly patients were very/extremely satisﬁed
from the treatment. The US evaluation at 12 months, compared
to baseline, did not show any signiﬁcant variation in both
groups.
DISCUSSION
The results of this study show that PRP treatment provides
satisfactory results in young subjects with Achilles recalcitrant
non-insertional tendinopathy reducing pain and improving
function. These ﬁndings are in agreementwith previous literature
data in patients suﬀering from Achilles, patellar, and elbow
tendinopathies (Andia and Abate, 2012; Andia and Maﬀulli,
2013; Andia et al., 2014). It is current opinion that the
therapeutic activity of PRP is mainly due to the release
of several growth factors (GFs), which can act on diﬀerent
aspects of tendon repair, including angiogenesis, chemotaxis, and
TABLE 3 | Ultrasound (US) findings at baseline in young and elderly
patients.
Young Elderly p
US degeneration
Mild 10 (27.7%) 5 (27.7%) 0.7
Moderate 19 (52.7%) 9 (50%) 0.9
Severe 7 (19.4%) 4 (11.1%) 0.9
Neovessels
Absent 6 (36.6%) 5 (27.7%) 0.5
Present 30 (83.3%) 13 (72.2%) 0.5
(1+) 8 (26.6%) 7 (53.8%) 0.1
(2+) 17 (56.6%) 4 (30.7%) 0.2
(3+) 3 (10%) 1 (7.6%) 0.7
(4+) 2 (6.6%) 1 (7.6%) 0.5
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TABLE 4 | Victorian Institute of Sports Assessment- Achilles questionnaire
(VISA-A) score during follow-up in young and elderly patients (intra-group
comparison).
VISA-A
Young p Elderly p
Baseline 50.3 ± 8.8 48.7 ± 7.6
1 month 56.8 ± 9.7 0.01 54.4 ± 7.1 0.04
3 months 68.7 ± 8 0.000 56.6 ± 4.9 0.002
6 months 72.4 ± 7.9 0.000 59.3 ± 8 0.000
12 months 76.1 ± 6.6 0.000 61.1 ± 9.4 0.000
cell proliferation by activating intracellular signal-transduction
pathways (Anitua et al., 2006; de Mos et al., 2008; Abate et al.,
2015).
In the short term (1–3 months), GFs can directly stimulate
tenocytes to produce extracellular matrix, and promote neoﬁbrils
formation and remodeling. Indeed, it is well known that the
Growth Hormone/Insulin-like GF-1 axis plays a central role in
the regulation of human collagen turnover in musculo-tendinous
tissue (Doessing et al., 2010; Andia and Abate, 2013). Insulin-
like GF-1 stimulates collagen formation (Abrahamsson et al.,
1991) and may also inhibit protein degradation, which is an eﬀect
of potential importance during immobilization periods when
there is a net protein loss (Ye et al., 2013). PRP-released GFs
and cytokines can also bind to ﬁbrin and to proteoglycans in
the extracellular matrix, constituting a storage pool that can be
secondarily released by metalloproteases (Magra and Maﬀulli,
2005; Nurden, 2011). Actually, the mechanism of action is
yet more complex, because the tissue outcomes may depend
on the balance between plasma and platelet proteins (de Mos
et al., 2008). However, the life-span of GFs and cytokines is
relatively short even if repeated PRP injections can favor a
better and long lasting action of platelet-derived GFs. So, it
is conceivable that their eﬀects can progressively fade until
complete exhaustion.
Therefore, the persistent eﬃcacy in the long-term (6–
12 months), more than on a direct stimulation, probably
relies on the activation of resident tendon stem/progenitor
cells (TSPCs), which have been recently identiﬁed in tendons
tissue from diﬀerent animal species (Bi et al., 2007; Tempfer
et al., 2009; Rui et al., 2010; Zhang et al., 2011; Mienaltowski
et al., 2013). Like stem cells present in adult tissues, TSPCs
are believed to be the source of newly diﬀerentiated tenocytes,
responsible for maintaining adequate tenocyte numbers in
the tissue throughout life and replenishing them after injury.
Compared to bone marrow-derived mesenchymal stem cells,
TSPCs express high levels of Scleraxis (a tendon-enriched
speciﬁc transcription factor) and tenomodulin (a marker of
adult tenocytes) and are able to form tendon and enthesis-like
tissues when implanted in vivo. Morphologically, TSPCs possess
smaller cell bodies and larger nuclei than ordinary tenocytes and
have a cobblestone-like morphology in conﬂuent cell cultures,
whereas tenocytes are highly elongated, a typical phenotype of
ﬁbroblast-like cells (Zhang et al., 2011). TSPCs also proliferate
more quickly than tenocytes in culture, and when implanted
in vivo exhibit the ability to regenerate tendon-like tissues (Bi
et al., 2007).
The biochemical niche, where TSPCs are embedded, is
of paramount relevance for their appropriate maintenance
and function. The importance of tendon extracellular matrix
in the maintenance of TSPC stemness is supported by a
recent study showing that rabbit Tendon Derived Stem Cells
cultured on decellularized tendon matrix proliferated at a
higher rate and had better stemness properties than those
cultured on plastic tissue culture surface (Zhang et al., 2011).
Moreover, GFs, as well as physiological loading, may increase
TSPC numbers, by “awakening” or reactivating these cells
(Sun et al., 2015). In conclusion, in young patients, it is
FIGURE 1 | Infra-group comparison at different follow-up times. Significant differences in VISA-A score were observed at 3, 6, and 12 months (p < 0.000) but
not at 1 month (p < 0.3).
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likely that PRP administration, associated to eccentric training
exercises, may activate the resident stem-cells, assuring the
prosecution of the healing mechanism for several months
afterward.
In contrast with ﬁndings in young subjects, this study
shows that the PRP injections promote positive response in
the clinical parameters, although less evident, in aged people.
In the present research, the elderly subjects at baseline had
similar VISA-A scores, symptoms duration and US degeneration.
However, whereas in the short term (after 1–3 months), they
showed an increase of VISA-A scores, although less relevant
than in young subjects, in the medium and long-term (6–
12 months) no further signiﬁcant clinical improvement was
observed. These results are not surprising, taking into account
diﬀerent factors.
First, aging is associated with a decline of plasma levels
of Insulin-like GF-1 (Rudman et al., 1981; Zadik et al.,
1985; Leifke et al., 2000; Moller et al., 2009; Boesen et al.,
2014), and platelets of aged people release minor amounts of
GFs. In this respect, Cho et al. (2011) and Lohmann et al.
(2012) found that mesenchymal stem cells’ proliferation was
higher with PRP from young donors, and that mesenchymal
stem cells cultured with PRP from elder donors presented
a senescent phenotype (Lohmann et al., 2012). Second, and
most importantly, advanced age is associated to a numerical
and/or functional deﬁcits in resident populations of tenocytes
and/or TSPCs. Senescent tenocytes become longer and thinner
and have decreased protein synthesis, producing collagen ﬁbers
more disoriented with more variations in thickness. They also
show a decrease in mucopolysaccharides, glycoaminoglycan,
chondroitin sulfate, dermatan sulfate and in water content
(Ippolito et al., 1980; Riley et al., 1994; Arnesen and Lawson,
2006; Thorpe et al., 2010; Ruzzini et al., 2014). Moreover,
senescent cells are characterized by the elevated expression
of senescent cell markers (β-gal), senescence-associated genes
(p53, p21, and p16INK4a, metalloproteases, ADAMTS), and
pro-inﬂammatory cytokines (Dimri et al., 1995; Campisi and
d’Adda di Fagnana, 2007; Russo et al., 2015). Age-related
changes in tenocyte behavior can be also responsible for
altered migration and proliferation rate. Tsai et al. (2011) in
an in vitro experiment performed on tenocytes derived from
young, middle-age and old Sprague–Dawley rats, showed that
decline in proliferation is directly correlated to aging and
that aged tenocytes tend to stop in G0/G1 cellular phase.
These results have been conﬁrmed by several authors (Thorpe
et al., 2010; Klatte-Schultz et al., 2012; Kostrominova and
Brooks, 2013; Torricelli et al., 2013). Aged TSPC show similar
characteristics, namely a profound TSPC self-renewal deﬁcit
accompanied with premature entry into cellular senescence;
signiﬁcant changes in the expression of genes regulating cell
adhesion, migration, cytoskeleton (scleraxis and tenomodulin),
dysregulated cell-matrix interactions and actin dynamics have
been also observed (Kohler et al., 2013; McCharty and
Hannaﬁn, 2014). Interestingly, Zhou et al. (2010) showed that
aged TSPCs formed adipocytes more readily than younger
cells and expressed higher levels of adipogenic markers
(PPARγ2, C/EBPa, and leptin) following induction. These
data may help to explain the higher levels of adipose tissue
normally associated with older tendons (Kannus and Jozsa,
1991), a pattern similar to that observed in bone marrow,
where adiposity was found to correlate inversely with the
functionality of hematopoietic stem/progenitor cells (Naveiras
et al., 2009).
Therefore, a large number of concordant and sound biological
data may explain why in aged persons PRP preparations
can be less eﬀective in promoting the activation of tenocytes
and their progenitors cells, and therefore long-term tissue
healing.
The ﬁndings of the present study can be hardly compared to
those found in literature. Indeed, only few authors evaluated the
impact of age on the therapeutic response to PRP (Ferrero et al.,
2012; Boesen et al., 2014; Filardo et al., 2014). In these studies age
resulted not inﬂuent on the outcomes, but the mean age of the
patients was signiﬁcantly lower, and aged persons were under-
represented in the samples.
Some limitations of our research must be acknowledged. First,
as well as for all the studies on PRP therapeutic activity, a
key aspect to consider is the composition of the product used,
because it cannot be excluded that other PRP formulations,
diﬀerent for cell type content, platelet concentration, storage
modalities, activation methods, and protocol for therapeutic
applications, could be more beneﬁcial in aged people (Abate
et al., 2012; Andia and Abate, 2012). Second, the data were
retrospectively collected. However, in this respect, it must be
observed that the patient’s selection was very careful and only
those who had speciﬁc inclusion/exclusion criteria and were
followed with a ﬁxed experimental protocol were evaluated.
Third, activity scales (i.e., Tegner Scale) was not collected; at
this regard, it must be noted that sedentary lifestyle, which
is more common in elderly subjects, may negatively inﬂuence
the main outcomes of the study. In the future, a prospective
trial, using PRP with higher platelet concentration, or with
the addition of exogenous GFs, and enrolling a consistent
number of subjects, will allow more sound and deﬁnitive
conclusions.
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